Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FluMist warning letter

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Manufacturing deficiencies at MedImmune's Liverpool, U.K. manufacturing facility for the live intranasal flu vaccine FluMist are not expected to affect the availability of the influenza vaccine for the 2007-2008 flu season, according to FDA. The agency issued a warning letter to MedImmune May 24, citing the company for several significant deviations from current good manufacturing practice in the manufacture of FluMist bulk monovalent lots stemming from an inspection between March 21 and March 27. MedImmune said it expects to have 7 million doses of FluMist available for the 2007-2008 influenza season. The deficiencies will delay approval of MedImmune's sBLA for FluMist seeking to extend the age indication for the vaccine. FDA issued a "complete response" letter for the sBLA May 25, pending resolution of the outstanding issues...

You may also be interested in...



FTC Commissioner Changes Could Impact Pharma Mergers, Scrutiny Of Biosimilars Uptake

President Biden’s picks to fill two commissioner posts may shift dynamics on pharmaceutical industry enforcement. Rohit Chopra’s nomination to Consumer Financial Protection Bureau removes strong critic of pharma mergers.

Prices Plunge As Xarelto Generics Arrive In India

More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.

Device Week, 21 January 2021 – EY M&A Firepower; JPM, NANS Events Highlights; CorWave Profile

In this week’s podcast, Medtech Insight's managing editor Marion Webb and deputy editor Reed Miller discuss highlights from the recent J.P. Morgan Healthcare and North American Neuromodulation Society (NANS) virtual meetings. And London-based reporter Barnaby Pickering profiles start-up CorWave SA, which developed a left ventricular assist device for treating end-stage heart failure.

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel